NZ711766B2 - Compositions and methods for immunotherapy - Google Patents
Compositions and methods for immunotherapy Download PDFInfo
- Publication number
- NZ711766B2 NZ711766B2 NZ711766A NZ71176614A NZ711766B2 NZ 711766 B2 NZ711766 B2 NZ 711766B2 NZ 711766 A NZ711766 A NZ 711766A NZ 71176614 A NZ71176614 A NZ 71176614A NZ 711766 B2 NZ711766 B2 NZ 711766B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cell
- antigen
- tumor
- immunoresponsive cell
- polypeptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 7
- 238000009169 immunotherapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 34
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 20
- 239000003446 ligand Substances 0.000 claims abstract description 13
- 244000052769 pathogen Species 0.000 claims abstract description 5
- 230000028993 immune response Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 31
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 15
- 102100032937 CD40 ligand Human genes 0.000 claims description 13
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 12
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 11
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 11
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
- -1 EGP-40 Proteins 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 9
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 7
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 206010062016 Immunosuppression Diseases 0.000 abstract 2
- 108010083359 Antigen Receptors Proteins 0.000 abstract 1
- 102000006306 Antigen Receptors Human genes 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000003042 antagnostic effect Effects 0.000 description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Abstract
The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhanced immune-activating properties. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhanced immune-activating properties.
Description
involving stimulation of an immune response, such as targeted T cell therapies. Accordingly, novel therapeutic strategies for treating neoplasia are urgently required.
SUMMARY OF THE INVENTION In a first aspect, the present invention provides an isolated immunoresponsive cell comprising: a. a chimeric antigen receptor (CAR) that binds to an antigen, wherein the binding of the CAR to the antigen is capable of activating the immunoresponsive cell, and b. a soluble single-chain variable fragment (scFv) that binds to a polypeptide that has immunosuppressive activity or immunostimulatory activity.
In a second aspect, the present invention provides a composition comprising the immunoresponsive cell of the first aspect.
In a third aspect, the present invention provides use of the immunoresponsive cell of the first aspect or the composition of the second aspect in the preparation of a medicament for reducing tumor burden in a subject, and/or for increasing survival of a subject having a neoplasm, and/or for preventing and/treating neoplasm.
In a fourth aspect, the present invention provides a method for producing an isolated immunoresponsive cell of the first aspect, the method comprising introducing into an isolated antigen-specific immunoresponsive cell a nucleic acid sequence that encodes a single-chain variable fragment (scFv) that binds to a polypeptide that has immunosuppressive activity or immunostimulatory activity, wherein the antigen-specific immunoresponsive cell comprises a CAR that binds to an antigen.
In a fifth aspect, the present invention provides a nucleic acid composition comprising a first nucleic acid sequence encoding a CAR that binds to an antigen, and a second nucleic acid sequence encoding a soluble single-chain variable fragment (scFv) that binds to a polypeptide having immunosuppressive activity or immunostimulatory activity.
In a sixth aspect, the present invention provides a kit for treatment of a neoplasm, a pathogen infection, an autoimmune disorder, and/or an allogeneic transplant, the kit comprising an immunoresponsive cell of the first aspect, or the nucleic acid composition of the fifth aspect.
The present invention generally provides immunoresponsive cells (e.g., T cells, Natural Killer (NK) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells), expressing an antigen binding receptor (e.g., CAR or TCR) having immune cell activating activity and a single-chain variable fragment (scFv) that binds an antigen having immunosuppressive activity (e.g., CD47, PD-1, CTLA-4, and ligands thereof), thereby reducing or eliminating the immunosuppressive activity of the antigen.
The invention further provides immunoresponsive cells (e.g., T cells, Natural Killer (NK) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells), expressing an antigen binding receptor (e.g., CAR or TCR) having immune cell activating activity and a single-chain variable fragment (scFv) that binds an antigen having immunostimulatory or proinflammatory activity (e.g., CD28, OX-40, 4-1BB, CD40 and ligands thereof), thereby enhancing the immunostimulatory activity of the antigen.
The invention further provides immunoresponsive cells (e.g., T cells, Natural Killer (NK) cells, cytotoxic T lymphocytes (CTLs), and regulatory T cells), expressing an antigen binding receptor (e.g., CAR or TCR) having immune cell activating activity and CD40L, for example, exogenous CD40L (CD40L that has been introduced directly or indirectly into the cell (for example, via a vector of naked nucleic acid comprising a nucleic acid sequence encoding CD40L), as compared to endogenous CD40L arising in the cell itself), thereby enhancing the immunostimulatory activity of the antigen.
Accordingly, the invention provides methods of using such immunoresponsive cells for the treatment of neoplasia, infectious disease, and other pathologies.
In one aspect, the invention provides an isolated immunoresponsive cell having an antigen recognizing receptor that binds an antigen, where the binding activates the immunoreponsive cell, and a soluble single-chain variable fragment (scFv) that binds a polypeptide that has immunosuppressive activity or immunostimulatory activity.
In another aspect, the invention provides a method of treating or preventing neoplasia in a subject, the method comprising administering, to the subject, an BRIEF DESCRIPTION OF THE FIGURES The following Detailed Description, given by way of example, but not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying drawings.
Figure 1 depicts T cells modified to express the chimeric antigen receptor (CAR) alone or in combination with secretable scFv (e.g. PD-1, PD-Ll, CTLA-4, or CD47). T cells modified to express the chimeric antigen receptor (CAR) alone are subject to suppression within the hostile tumor microenvironment. Without being bound to a particular theory, further modification of these cells to express secretable scFv to block immunosuppressive signaling has improved anti-tumor function due to their ability to modulate the tumor microenvironment and resist suppressive factors. Armored CARs: T Cells modified to express the chimeric antigen receptor (CAR) alone are subject to suppression within the hostile tumor microenvironment. Further modification of these cells to express secretable scFv (e.g. PD-1, PD-L 1, CTLA-4 or CD47 blocking) have improved antitumor function due to their ability to modulate the tumor microenvironment and resist suppressive factors.
Figures 2A and 2B depict the structure of secretable anti-CD47 scFv constructs. Figure 2A depicts the structure of a secretable anti-CD47 scFv designed to include a kappa ( ) leader sequence to allow exportation of this protein. The variable heavy (V ) and light (V ) chains were linked with a serine glycine linker (G S) and a myc-tag peptide was included to allow detection of the scFv. Figure 2B depicts the secretable scFv was linked to the 1928z CAR construct using a P2A element as shown. Secretable anti-CD47 scFv structure - (a) Secretable anti-CD47 scFv was designed to include a kappa(K') leader sequence to allow exportation of this protein. The variable heavy(V ) and light(V ) were linked with a serine glycine linker(G4S) and a myc-tag peptide was included to allow detection of the scFv. (b) The secretable scFv was linked to the 19282 CAR construct using a P2A element as shown.
Figure 3 depicts the B6Hl2.2 scFv sequence operably linked to a Kappa leader sequence [SEQ ID NO:18]. The variable heavy (V ) and variable light (V ) sequences of the B6Hl2.2 hybridoma were PCR amplified with a kappa leader sequence, a c-myc tag and joined with a serine glycine linker. The nucleic acid sequence and amino acid translation are shown.
Figure 4 depicts B6Hl2.2 scFv sequence operably linked to a CDS leader sequence [SEQ ID NO:19]. The variable heavy (V ) and variable light (V ) sequences of the B6Hl2.2 hybridoma were PCR amplified with a CDS leader sequence, a c-myc tag and joined with a serine glycine linker. The nucleic acid sequence and amino acid translation are shown.
Figure 5 depicts the nucleic acid sequence of the 1928z-2A-B6Hl2.2 (kappa leader) construct [SEQ ID NO:20]. The B6Hl2.2 scFv sequence was cloned into an SFG expression vector for expression with the CD19-targeted 1928z CAR. A P2A element was used to join the two elements, as shown. the inhibitory CTLA-4 T cell receptor on both infused CAR modified T cells and endogenous anti- tumor T cells enhancing anti-tumor effector function (3), or induced to secrete an scFv antagonistic to the CD47 receptor expressed on the tumor cell reversing the cloaking the tumor cell from recognition by the host innate anti-tumor immune response leading to recognition and eradication of tumor by host macrophages. Genetically engineering "armored" CAR T cells designed to overcome the "hostile tumor microenvironment". CAR-T cells may alternatively be additionally modified to secrete antagonistic scFvs with immune regulatory functions. Upon activation of the CAR to cognate antigen (1), armored CAR modified T cells may be induced to secrete scFvs antagonistic to the inhibitory PD-1 T cell receptor on both infused CAR modified T cells and endogenous anti-tumor T cells enhancing anti-tumor effector function(2), induced to secrete scFvs antagonistic to the inhibitory CTLA-4 T cell receptor on both infused CAR modified T cells and endogenous anti-tumor T cells enhancing antitumor effector function(3), or induced to secrete an scFv antagonistic to the CD47 receptor expressed on the tumor cell reversing the cloaking the tumor cell from recognition by the host innate anti-tumor imune response leading to recognition and eradication of tumor by host macrophages.
Figure 22A-22D depict constitutive expression of CD40L by human T-cells. (A) Schematic of retroviral construct encoding human CD40L vector; LTR, long terminal repeat; SD, SA, splice donor and acceptor; Ψ, packaging element. (B) Flow cytometry of CD4+ and CD8+ CD40L-modified T-cells following retroviral gene transfer; x- axis APC-conjugated anti-human CD40L (CD154). (C) Enhanced proliferation of CD40L-modified T-cells compared to mock transduced T-cells. (D) Enhanced secretion of soluble CD40L (sCD40L), IFN-γ, and GM-CSF of CD40L-modified T-cells compared to mock transduced T-cells. All results are representative of at least three separate experiments. (* denotes statistical significance) Figure 23A and 23 B depict augmented immunogenicity of CD40+ Tumor cells by CD40L-modified T-cells. (A) Flow cytometry showing upregulation of co-stimulatory molecules (CD80 and CD86), adhesion molecules (CD54, CD58, and CD70) HLA molecules (HLA Class I and HLA-DR), and the Fas-death receptor (CD95) on DOHH2 tumor cell line following co-culture with CD40L-modified T-cells (solid line) compared to culture with mock- transduced T-cells from the same donor (gray line). (B) CD40- tumor (NALM6 shown) demonstrating no phenotypic changes following co-culture with CD40L-modified T-cells. All results are representative of at least three separate experiments.
Figure 24A and 24B depict augmented immunogenicity of CLL cells by autologous CD40L-modified T-cells. (A) Flow cytometry of patient derived CD40L-modified T-cells following retroviral gene transfer with CD40L containing retroviral vector; x- axis APC- conjugated anti-human CD40L (CD154). (B) Flow cytometry showing upregulation of co- stimulatory molecules (CD80 and CD86), adhesion molecules (CD54, CD58, and CD70) HLA molecules (HLA Class I and HLA-DR), and the Fas-death receptor (CD95) on CLL cells after co-culturing with autologous CD40L-modified T-cells (solid line) compared to co-cultures with mock-transduced T-cells from the same donor (gray line). All results are representative of at least three separate experiments.
Claims (27)
1. An isolated immunoresponsive cell comprising: a. a chimeric antigen receptor (CAR) that binds to an antigen, wherein the binding of the CAR to the antigen is capable of activating the immunoresponsive cell, b. a soluble single-chain variable fragment (scFv) that binds to a polypeptide that has immunosuppressive activity or immunostimulatory activity.
2. The isolated immunoresponsive cell of claim 1, wherein the antigen is a tumor antigen or a pathogen antigen.
3. The isolated immunoresponsive cell of claim 1, wherein the soluble scFv is secreted by the cell.
4. The isolated immunoresponsive cell of any one of claims 1-3, wherein the CAR and/or the scFv is expressed from a vector.
5. The isolated immunoresponsive cell of any one of claims 1-4, wherein the cell is a T cell, or a Natural Killer (NK) cell.
6. The isolated immunoresponsive cell of any one of claims 1-5, wherein the cell is a T cell.
7. The isolated immunoresponsive cell of claim 5 or 6, wherein the T cell is a cytotoxic T lymphocyte (CTL) or a regulatory T cell.
8. The isolated immunoresponsive cell of any one of claims 1-7, wherein the immunoresponsive cell is autologous.
9. The isolated immunoresponsive cell of any one of claims 1-9, wherein the antigen is a tumor antigen selected from the group consisting of CD19, MUC16, MUC1, CAIX, CEA, CDS, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, a cytomegalovirus (CMV) infected cell antigen, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, Fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13Ra2, K-light chain, DR, LeY, L1 cell adhesion molecule, MAGE- A1, Mesothelin, NKG2D ligands, NY-ESO-1, oncofetal antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, and WT-1.
10. The isolated immunoresponsive cell of any one of claims 1-9, wherein the immunosuppressive polypeptide is selected from the group consisting of CD47, PD-1, CTLA- 4, and ligands thereof.
11. The isolated immunoresponsive cell of any one of claims 1-9, wherein the immunostimulatory polypeptide is selected from the group consisting of CD28, OX-40, 4-1BB, and ligands thereof.
12. The isolated immunoresponsive cell of any one of claims 1-11, wherein the antigen is CD19 or MUC16.
13. The isolated immunoresponsive cell of any one of claims 1-12, wherein the CAR comprises an intracellular signaling domain that comprises a C D3ζ-chain.
14. The isolated immunoresponsive cell of claim 13, wherein the intracellular signaling domain of the CAR further comprises a signaling domain of CD97, CD11a-CD18, CD2, ICOS, CD27, CD154, CDS, OX40, 4-1BB, CD28, or a combination thereof.
15. The isolated immunoresponsive cell of any one of claims 1-14, wherein the CAR a) binds to CD19 and comprises an intracellular signaling domain that comprises a C D3ζ-chain and a signaling domain of CD28, or b) binds to MUC16 and comprises an intracellular signaling domain that comprises a C D3ζ-chain and a signaling domain of CD28.
16. The isolated immunoresponsive cell of any one of claims 1-15, wherein the soluble scFv enhances an immune response of the immunoresponsive cell.
17. A composition comprising the immunoresponsive cell of any one of claims 1-16.
18. The composition of claim 17, which is a pharmaceutical composition further comprising a pharmaceutically acceptable excipient.
19. Use of the immunoresponsive cell of any one of claims 1-16 or the composition of claim 17 or 18 in the preparation of a medicament for reducing tumor burden in a subject, and/or for increasing survival of a subject having a neoplasm, and/or for preventing and/treating neoplasm.
20. The use of claim 19, wherein the medicament reduces the number of tumor cells, reduces tumor size, and/or eradicates the tumor.
21. The use of claim 19 or 20, wherein the tumor or neoplasm is selected from the group consisting of blood cancer, B cell leukemia, multiple myeloma, lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer.
22. The use of claim 21, wherein: a) the tumor or neoplasm is B cell leukemia, the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; b) the tumor or neoplasm is multiple myeloma, the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; c) the tumor or neoplasm is acute lymphoblastic leukemia (ALL), the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; d) the tumor or neoplasm is chronic lymphocytic leukemia, the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; e) the tumor or neoplasm is non-Hodgkin's lymphoma, the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; f) the tumor or neoplasm is blood cancer, the antigen is CD19, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof; or g) the tumor or neoplasm is ovarian, the antigen is MUC16, and the polypeptide that has immunosuppressive activity is selected from the group consisting of CD47, PD-1, CTLA-4, and ligands thereof.
23. A method for producing an isolated immunoresponsive cell of any one of claims 1-16, the method comprising introducing into an isolated antigen-specific immunoresponsive cell a nucleic acid sequence that encodes a single-chain variable fragment (scFv) that binds to a polypeptide that has immunosuppressive activity or immunostimulatory activity, wherein the antigen-specific immunoresponsive cell comprises a CAR that binds to an antigen.
24. A nucleic acid composition comprising a first nucleic acid sequence encoding a CAR that binds to an antigen, and a second nucleic acid sequence encoding a soluble single-chain variable fragment (scFv) that binds to a polypeptide having immunosuppressive activity or immunostimulatory activity.
25. The nucleic acid composition of claim 24, which is a vector.
26. A kit for treatment of a neoplasm, a pathogen infection, an autoimmune disorder, and/or an allogeneic transplant, the kit comprising an immunoresponsive cell of any one of claims 1- 16 or the nucleic acid composition of claim 24 or 25.
27. The kit of claim 26, wherein the kit further comprises written instructions for using the cell for the treatment of a subject having a neoplasm, a pathogen infection, an autoimmune disorder, and/or an allogeneic transplant. Memorial Sloan-Kettering Cancer Center By the Attorneys for the Applicant SPRUSON & FERGUSON Per:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ751082A NZ751082B2 (en) | 2013-02-26 | 2014-02-26 | Compositions and methods for immunotherapy |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769543P | 2013-02-26 | 2013-02-26 | |
| US61/769,543 | 2013-02-26 | ||
| PCT/US2014/018667 WO2014134165A1 (en) | 2013-02-26 | 2014-02-26 | Compositions and methods for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ711766A NZ711766A (en) | 2021-06-25 |
| NZ711766B2 true NZ711766B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210061877A1 (en) | Chimeric antigen receptors and methods of use thereof | |
| US11034763B2 (en) | Flag tagged CD19-CAR-T cells | |
| CN108884164B (en) | Modified cells for immunotherapy | |
| Ruella et al. | Adoptive immunotherapy for cancer | |
| AU2014223601B2 (en) | Compositions and methods for immunotherapy | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| US20220378911A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| Qian et al. | Cell transfer therapy for cancer: past, present, and future | |
| AU2019243453A1 (en) | Methods of making and using guidance and navigation control proteins | |
| DK3029137T3 (en) | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF | |
| Zuo et al. | Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers | |
| KR20190140756A (en) | A bispecific antibody binding to natural killer cells and an use thereof | |
| CA3052803A1 (en) | Maximizing t-cell memory and compositions and methods therefor | |
| Mason et al. | Cancer immunotherapy | |
| A Baeuerle et al. | Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer | |
| WO2021173560A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| US20220280564A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| NZ711766B2 (en) | Compositions and methods for immunotherapy | |
| NZ751082B2 (en) | Compositions and methods for immunotherapy | |
| WO2023044991A1 (en) | Antibody specifically targeting tumor epcam antigen and application thereof | |
| Rodríguez-Cruz et al. | T Cell-Based Immunotherapy |